Trial Profile
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 28 Mar 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary)
- Indications Glioblastoma
- Focus Pharmacokinetics
- 13 Aug 2018 Status changed from recruiting to completed.
- 27 Oct 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
- 27 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.